Analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report $1.70 billion in sales for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Regeneron Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.77 billion and the lowest estimate coming in at $1.61 billion. Regeneron Pharmaceuticals posted sales of $1.58 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.6%. The company is expected to report its next quarterly earnings results on Thursday, February 14th.
On average, analysts expect that Regeneron Pharmaceuticals will report full year sales of $6.47 billion for the current year, with estimates ranging from $6.32 billion to $6.56 billion. For the next financial year, analysts anticipate that the company will report sales of $7.16 billion, with estimates ranging from $6.81 billion to $7.83 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, beating the consensus estimate of $4.94 by $0.93. The company had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.64 billion. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.99 EPS.
REGN has been the subject of several research analyst reports. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $370.00 to $396.00 and gave the company an “equal weight” rating in a research note on Friday, July 13th. Argus boosted their price target on shares of Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a “buy” rating in a research note on Monday, July 16th. Canaccord Genuity restated a “$367.74” rating and set a $304.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, July 19th. Jefferies Financial Group restated a “hold” rating and set a $340.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, July 24th. Finally, TheStreet upgraded shares of Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, July 25th. Two equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $410.95.
In other news, Director Michael S. Brown sold 2,000 shares of the company’s stock in a transaction on Thursday, September 27th. The shares were sold at an average price of $392.26, for a total value of $784,520.00. Following the completion of the sale, the director now owns 2,000 shares in the company, valued at approximately $784,520. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $380.49, for a total transaction of $570,735.00. Following the completion of the sale, the director now owns 1,500 shares of the company’s stock, valued at approximately $570,735. The disclosure for this sale can be found here. In the last quarter, insiders sold 110,052 shares of company stock valued at $44,651,762. Company insiders own 12.42% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Hawaii grew its stake in shares of Regeneron Pharmaceuticals by 19.3% in the 3rd quarter. Bank of Hawaii now owns 2,058 shares of the biopharmaceutical company’s stock worth $832,000 after acquiring an additional 333 shares in the last quarter. CIBC World Markets Inc. grew its stake in shares of Regeneron Pharmaceuticals by 183.3% in the 3rd quarter. CIBC World Markets Inc. now owns 8,968 shares of the biopharmaceutical company’s stock worth $3,623,000 after acquiring an additional 5,802 shares in the last quarter. FMR LLC grew its stake in shares of Regeneron Pharmaceuticals by 17.0% in the 3rd quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock worth $2,026,867,000 after acquiring an additional 728,104 shares in the last quarter. American International Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 4.8% in the 3rd quarter. American International Group Inc. now owns 36,489 shares of the biopharmaceutical company’s stock worth $14,743,000 after acquiring an additional 1,664 shares in the last quarter. Finally, Todd Asset Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $17,969,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.
NASDAQ:REGN opened at $356.66 on Friday. The firm has a market capitalization of $38.64 billion, a PE ratio of 26.60, a P/E/G ratio of 1.20 and a beta of 1.34. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.49 and a quick ratio of 2.92. Regeneron Pharmaceuticals has a twelve month low of $281.89 and a twelve month high of $416.49.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.